¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"neutron activation analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement activation
    º¸Ã¼È°¼ºÈ­, µµ¿òüȰ¼ºÈ­
  • photochemical activation
    ±¤È­ÇÐȰ¼ºÈ­
  • sleep activation
    ¼ö¸éȰ¼ºÈ­
  • ventricular activation
    ½É½ÇȰ¼ºÈ­
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
  • antigen analysis
    Ç׿øºÐ¼®
  • arterial blood gas analysis
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • age-period cohort analysis
    ¿¬·É±â°£ÄÚȣƮºÐ¼®
  • analysis
    ºÐ¼®
  • birth cohort analysis
    Ãâ»ýÄÚȣƮºÐ¼®
  • clinical decision analysis
    ÀÓ»óÀÇ»ç°áÁ¤ºÐ¼®
  • clonal analysis
    Ŭ·ÐºÐ¼®
  • cluster analysis
    ¹«¸®ºÐ¼®
  • cohort analysis
    ÄÚȣƮºÐ¼®
  • computer-assisted semen analysis
    ÄÄÇ»ÅÍÁ¤¾×°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activation gate
    °³¹æ°ü¹®
  • activation process
    Ȱ¼ºÈ­°úÁ¤
  • complement activation
    µµ¿òüȰ¼º, º¸Ã¼È°¼º
  • photochemical activation
    ±¤È­ÇÐȰ¼ºÈ­
  • sleep activation
    ¼ö¸éȰ¼º
  • ventricular activation
    ½É½ÇÈïºÐ
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
  • analysis
    ºÐ¼®
  • age-period cohort analysis
    ¿¬·É±â°£ÄÚȣƮºÐ¼®
  • antigen analysis
    Ç׿øºÐ¼®
  • birth cohort analysis
    Ãâ»ýÄÚȣƮºÐ¼®
  • case analysis
    Áõ·ÊºÐ¼®
  • clinical decision analysis
    ÀÓ»óÀÇ»ç°áÁ¤ºÐ¼®
  • clonal analysis
    Ŭ·ÐºÐ¼®
  • cluster analysis
    ¹«¸®ºÐ¼®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • polyclonal activation
    ´Ù(¼ö)Ŭ·ÐȰ¼º, ¿©·¯¹«¸®È°¼º
  • DNA sequence analysis
    DNA ¼­¿­ºÐ¼®
  • Data analysis
    Á¤º¸ºÐ¼®
  • Decision analysis
    °áÁ¤ºÐ¼®
  • amniotic fluid analysis
    ¾ç¼öºÐ¼®
  • analysis
    ºÐ¼®
  • analysis of variance technique
    ºÐ»ê±â¼úºÐ¼®
  • analysis, antigen
    Ç׿øºÐ¼®
  • frequency analysis
    Á֯ļöºÐ¼®
  • gas analysis
    °¡½ººÐ¼®.
  • gas analysis
    °¡½ººÐ¼®
  • gasometric analysis
    ±âüÁ¤·®ºÐ¼®.
  • gastric analysis
    À§¾×°Ë»ç(¡­ËþÞÛ).
  • gene analysis
    À¯ÀüÀںм®(¡­ÝÂà°).
  • gene analysis
    À¯ÀüÀںм®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • neutron leakage
    Áß¼ºÀÚÀ¯½Ç.
  • neutron radiation therapy
    Áß¼ºÀÚ¹æ»ç¼±Ä¡·á
  • neutron ray
    Áß¼ºÀÚ¼±
  • activation
    Ȱ¼ºÈ­
  • activation
    Ȱ¼ºÈ­(üÀàõûù).
  • activation detector
    Ȱ¼ºÈ­ ŽÁö±â
  • activation energy
    Ȱ¼ºÈ­¿¡³ÊÁö
  • activation gate
    °³¹æ °ü¹®(ËÒÛÁμڦ)
  • activation process
    Ȱ¼ºÈ­°úÁ¤.
  • activation, polyclonal
    ´Ù¼¼Æ÷±ºÈ°¼º, ¿©·¯¹«¸®È°¼º
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • c3, activation
    C3, Ȱ¼º (¡­üÀàõ)
  • complement activation
    º¸Ã¼È°¼ºÀÛ¿ë(¡­üÀàõíÂéÄ), º¸Ã¼È°¼ºÈ­.
  • complement activation
    º¸Ã¼È°¼ºÀÛ¿ë
  • energy of activation
    Ȱ¼ºÈ­¿¡³ÊÁö.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • macrophage activation factor
    ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ(ÓÞãÝá¬øàüÀàõì×í­)
  • reciprocal activation
    »óº¸ Ȱ¼ºÈ­(ßÓÜÍüÀàõûù)
  • upstream activation sites
    À­ÂÊ È°¼ºÈ­(üÀàõûù)ÀÚ¸®
  • amino acid analysis
    ¾Æ¹Ì³ë»ê(ß«) ºÐ¼®(ÝÂà°)
  • analysis of variance
    ºÐ»êºÐ¼®(ÝÂߤÝÂà°)
  • conformational analysis
    ÀÔüÇüÅ ºÐ¼®(Ø¡ô÷û¡÷¾ÝÂà°)
  • control analysis
    ´ëÁ¶ ºÐ¼®(ÓßðÎÝÂà°)
  • covalent structure analysis
    °øÀ¯°áÇÕ ±¸Á¶ºÐ¼®(ÍìêóÌ¿ùêϰðãÝÂà°)
  • differential thermal analysis
    Â÷ ¿­ºÐ¼®(ó¬æðÝÂà°)
  • displacement analysis
    ´ëÄ¡ºÐ¼®(ÓÛöÇÝÂà°)
  • double isotope dilution analysis
    ÀÌÁß µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ì£ñìÔÒêÈêªáÈýüà·ÝÂà°)
  • elementary analysis
    ¿ø¼Ò ºÐ¼® (êªáÈÝÂà°)
  • elution analysis
    ¿ë¸® ºÐ¼® (éÁ×îÝÂà°)
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • fluctuation analysis
    ¿äµ¿ ºÐ¼®(èôÔÑÝÂà°)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TBNA total body neutron activation; treated but not admitted
SA salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame...
MEDPAR Medical Provider Analysis and Review; Medicare Provider Analysis and Review
MRA magnetic resonance angiography; main renal artery; marrow repopulation activity; medical record anal...
RAS   1) Reticular Activating(Activation) System
  2) Renal Artery Stenosis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NCT Neutron Capture Therapy
SANS Small angle neutron scattering
Kact Activation constants
AD activation domain
AF-1 Activation function 1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bite analysis
    ±³ÇÕ ºÐ¼®
    ±³ÇÕ°£ °ü°è³ª ±× Ç¥½Ã¸¦ ºÐ¼®ÇÏ´Â °Í.
  • case analysis
    Áõ·Ê ºÐ¼®
  • character analysis
    ¼º°Ý ºÐ¼®
  • cluster analysis
    ±ÕÁÖ±º ºÐ¼®
  • computerized image analysis
    ÄÄÇ»ÅÍ ¿µ»ó ºÐ¼®
  • continuous flow blood analysis
    Áö¼Ó¼º À¯µ¿ Ç÷¾× ºÐ¼®
  • dietary analysis
    ½ÄÀÌ ºÐ¼®
  • dynamic mechanical analysis
    µ¿Àû ±â°èÀû ºÐ¼®
  • ego analysis
    ÀÚ¾Æ ºÐ¼®
  • electron beam microporbe analysis
    ÀüÀÚ±¤ ¹Ì¼¼ Žħ ¿ä¼Ò ºÐ¼®, ÀüÀÚ±¤ ¹Ì¼¼ Žħ ºÐ¼®
  • electron microprobe analysis
    ÀüÀÚ ¹Ì¼¼ Žħ
  • elementary analysis
    ¿ø¼Ò ºÐ¼®
    À¯±â È­ÇÕ¹°¿¡ ÇÔÀ¯µÇ¾î ÀÖ´Â ¿ø¼ÒÀÇ Á¾·ù¸¦ °áÁ¤Çϰųª, ºñÀ²À» °áÁ¤ÇÏ´Â ºÐ¼® ¹æ¹ý. ÀüÀÚ¸¦ Á¤¼º ¿ø¼Ò ºÐ¼®, ÈÄÀÚ¸¦ Á¤·® ¿ø¼Ò ºÐ¼®À̶ó°í ÇÑ´Ù. Á¤¼º ¿ø¼Ò ºÐ¼®, Áï ¿ø¼Ò °ËÃâ¹ý¿¡¼­´Â À¯±â È­ÇÕ¹°À» ±¸¼ºÇϰí ÀÖ´Â °¢ ¿ø¼Ò¿¡ µû¶ó ¿©·¯ °¡Áö ¹æ¹ýÀÌ »ç¿ëµÇÁö¸¸, ¸ðµÎ À¯±â È­ÇÕ¹°À» ºÐÇØÇÏ¿© °£´ÜÇÑ ¹«±â È­ÇÕ¹°·Î °ËÃâÇÑ´Ù. Á¤·® ¿ø¼Ò ºÐ¼®, Áï ÇÔÀ¯·®À» °áÁ¤ÇÏ´Â ¹æ¹ý¿¡´Â äÃëÇÏ´Â ½Ã·áÀÇ ¾ç¿¡ µû¶ó¼­ »ó·®¹ý
  • Enlow Analysis
    ¿£·Î¿ì ºÐ¼®
  • frequency analysis
    ÁÖÆÄ ¼ö ºÐ¼®
  • in vivo analysis
    »ýü³» ºÐ¼®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
virus activation The mechanism by which latent viruses, such as genetically transmitted tumour viruses or prophages of lysogenic bacteria, are induced to replicate and are released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell lipopolysaccharides, glucocorticoid hormones, halogenated pyrimidines, ionizing radiation, ultraviolet light, and superinfecting viruses.
(12 Dec 1998)
cis activation <molecular biology> Activation of a gene by an activator located on the same chromosome i.e. Not by a diffusible product.
(18 Nov 1997)
complement activation The sequential activation of serum components c1 through c9, initiated by an erythrocyte-antibody complex or by microbial polysaccharides and properdin, and producing an inflammatory response.
(12 Dec 1998)
platelet activation A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug.
(12 Dec 1998)
neutrophil activation The process in which the neutrophil is stimulated by diverse substances, resulting in degranulation and/or generation of reactive oxygen products, and culminating in the destruction of invading pathogens. The stimulatory substances, including opsonised particles, immune complexes, and chemotactic factors, bind to specific cell-surface receptors on the neutrophil.
(12 Dec 1998)
EEG activation The low voltage, fast pattern of attentive wakefulness.
(05 Mar 2000)
trans-activation (genetics) Increased rate of gene expression directed by either viral or cellular proteins. These regulatory factors (diffusible gene products) act in trans -- that is, act on homologous or heterologous molecules of DNA. (cis-acting factors act only on homologous molecules.)
(12 Dec 1998)
energy of activation Energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction; usually expressed in the Arrhenius equation relating a rate constant to absolute temperature.
(05 Mar 2000)
enzyme activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1) activation by ions (activators); 2) activation by cofactors (coenzymes); and 3) conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
(12 Dec 1998)
juxtacrine activation Activation of target cells by membrane anchored growth factors, also used for activation of leucocytes by PAF bound to endothelial cell surface.
(18 Nov 1997)
feedback activation The activation of an enzyme by an end product of a biochemical pathway in which that enzyme plays a part. For example, the activation of factors VIII and V by thrombin during blood clotting.
(05 Mar 2000)
feed-forward activation The activation of an enzyme by a precursor of the substrate of that enzyme.
(05 Mar 2000)
upstream activation site A DNA sequence that regulates transcription like an enhancer but does notwork if its located downstream from a promoter.
(09 Oct 1997)
low-activation materials <radiobiology> In fission reactors, one is forced to deal with the radioactive byproducts of the fission process, but in fusion reactors one generally has a choice of what materials to expose to neutrons produced by the fusion process. A major problem for fusion reactors is developing materials (such as for the reactor vacuum vessel structure) which can be exposed to high levels of neutron bombardment without becoming permanently radioactive. Candidate structural materials which have relatively low induced radiactivation (generally relative to stainless steel) are known as low-activation materials, these include titanium, vanadium, and silicon-carbide.
(09 Oct 1997)
lymphocyte activation <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • factor analysis
    ÀÎÀÚ ºÐ¼®
  • harmonic analysis
    Á¶È­ ºÐ¼®;Á¶È­ ÇØ¼®;Á¶ÆÄ ºÐ¼®
  • high analysis
    (ºñ·á°¡)½Ä¹°ÀÇ ÇÊ¿ä ¾çºÐÀÇ 20% ÀÌ»óÀ» ÇÔÀ¯ÇÏ´Â
  • inputoutput analysis
    ÅõÀÔ»êÃâºÐ¼®
  • job analysis
    ÀÛ¾÷ ºÐ¼®
  • market analysis
    ½ÃÀå ºÐ¼®
  • network analysis
    (¼ö)ȸ·Î(¸Á) ÇØ¼®;³×Æ®¿öÅ©ºÐ¼®;(ȸ·Î¸Á ÇØ¼® ¼ö¹ýÀ» ÀÌ¿ëÇÏ¿© ÇÁ·ÎÁ§Æ®ÀÇ °èȹ °ü¸®¸¦ÇÔ
  • nonstandard analysis
    ÃÊÁØÇؼ®
  • philosphical analysis
    öÇÐÀû ºÐ¼®
  • pollen analysis
    ²É°¡·ç ºÐ¼®;È­ºÐÇÐ
  • qualitative analysis
    Á¤¼º ºÐ¼®
  • quantitative analysis
    Á¤·® ºÐ¼®
  • systems analysis
    (´É·ü,Á¤¹Ðµµ¸¦ ³ôÀ̱â À§ÇÑ) ½Ã½ºÅÛ ºÐ¼®
  • ultimate analysis
    ¿ø¼Ò ºÐ¼®
  • ultimate analysis
    ¿ø¼Ò ºÐ¼®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á